CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction

Clinical trial NCT06389305 · RECRUITING

Trial details

NCT number: NCT06389305
Sponsor: Beijing GoBroad Hospital
Status: RECRUITING
Phase: Not Applicable
Study type: INTERVENTIONAL

B-cell Acute Lymphoblastic Leukemia Acute Lymphoblastic Leukemia, in Relapse Refractory Acute Lymphoid Leukemia

Start date: 2024-05-27
Primary completion: 2026-05-30
Enrollment: 213

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.